SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bajaj Healthcare - Quaterly Results

13 Feb 2023 Evaluate
The sales declined to Rs. 1418.85 millions for the December 2022 quarter as compared to Rs. 1675.75 millions during the corresponding quarter last year.Net profit of the cmpany stood at Rs. 110.54 millions for the quarter ended December 2022 a decline of -36.64% from Rs. 174.45 millions  in the same quarter last year.Operating Profit reported a sharp decline to 286.99 millions from 310.29 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 1418.85 1675.75 -15.33 5148.48 5041.76 2.12 6798.89 6569.84 3.49
Other Income 0.72 1.98 -63.64 8.74 9.95 -12.16 14.44 69.13 -79.11
PBIDT 286.99 310.29 -7.51 886.61 942.91 -5.97 1199.45 1432.39 -16.26
Interest 67.36 28.45 136.77 155.12 81.38 90.61 126.24 82.96 52.17
PBDT 219.63 281.84 -22.07 731.49 861.53 -15.09 1073.21 1349.43 -20.47
Depreciation 69.23 48.59 42.48 199.34 133.97 48.79 176.36 161.24 9.38
PBT 150.40 233.25 -35.52 532.15 727.56 -26.86 896.85 1188.19 -24.52
TAX 39.86 58.80 -32.21 137.82 188.41 -26.85 182.98 357.11 -48.76
Deferred Tax -0.94 -0.90 4.44 -2.88 1.71 -268.42 -6.14 4.99 -223.05
PAT 110.54 174.45 -36.64 394.33 539.15 -26.86 713.87 831.08 -14.10
Equity 137.99 137.99 0.00 137.99 137.99 0.00 137.99 137.99 0.00
PBIDTM(%) 20.23 18.52 9.24 17.22 18.70 -7.92 17.64 21.80 -19.08

Bajaj Healthcare Share Price

348.95 -1.50 (-0.43%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×